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Abstract

Objectives: Caregiving burdens are a substantial concern in the clinical care of persons
with neurodegenerative disorders. In the Ontario Neurodegenerative Disease Research Initiative,
we used the Zarit’s Burden Interview (ZBI) to examine: (1) the types of burdens captured by the
ZBI in a cross-disorder sample of neurodegenerative conditions (2) whether there are categorical
or disorder-specific effects on caregiving burdens, and and (3) which demographic, clinical, and
cognitive measures are related to burden(s) in neurodegenerative disorders?
Methods/Design: N = 504 participants and their study partners (e.g., family, friends)
across: Alzheimer’s disease/mild cognitive impairment (AD/MCI; n = 120), Parkinson’s disease
(PD; n = 136), amyotrophic lateral sclerosis (ALS; n = 38), frontotemporal dementia (FTD; n =
53), and cerebrovascular disease (CVD; n = 157). Study partners provided information about
themselves, and information about the clinical participants (e.g., activities of daily living). We
used Correspondence Analysis to identify types of caregiving concerns in the ZBI. We then
identified relationships between those concerns and demographic and clinical measures, and a
cognitive battery.
Results: We found three components in the ZBI. The first was “overall burden” and was
(1) strongly related to increased neuropsychiatric symptoms (NPI severity r = 0.586, NPI distress
r = 0.587) and decreased independence in activities of daily living (instrumental ADLs r =
-0.566, basic ADLs r = -0.43), (2) moderately related to cognition (MoCA r = -0.268), and (3)
showed little-to-no differences between disorders. The second and third components together
showed four types of caregiving concerns: current care of the person with the neurodegenerative
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disease, future care of the person with the neurodegenerative disease, personal concerns of study
partners, and social concerns of study partners.
Conclusions: Our results suggest that the experience of caregiving in neurodegenerative
and cerebrovascular diseases is individualized and is not defined by diagnostic categories. Our
findings highlight the importance of targeting activities of daily living and neuropsychiatric
symptoms with caregiver-personalized solutions.
Keywords: Zarit’s burden interview, Correspondence analysis, Neurodegenerative
disorders, activities of daily living, neuropsychiatric symptoms
Key points:
● We identified multiple types of caregiving burden from the Zarit’s Burden Interview
across five neurodegenerative and cerebrovascular disorders.
● Overall burden showed strong relationships with neuropsychiatric symptoms (measured
via Neuropsychiatric Inventory - Questionnaire) and functional dependence (measured
via instrumental and basic activities of daily living).
● We found little to no differences between disorders
● Through our analyses we identified two questions that stood out with very high
responses, and these two questions briefly capture the four types of burdens we
identified: “Are you afraid of what the future holds for your relative?” and “Do you feel
your relative is dependent on you?”
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Caregiving concerns and clinical characteristics across disorders in the ONDRI study
Introduction
Informal caregivers are a critical and overlooked resource in the care of individuals with
neurodegenerative disorders 1. The personal strains of informal caregivers include physical,
financial, emotional, and social stressors 2,3. Caregivers can experience decreased health-related
quality of life 4,5, elevated rates of depression and anxiety 6,7, and impaired levels of cognition
compared to their age-matched peers 8. Informal caregivers of those with dementia provide
billions of dollars in uncompensated care annually 9. As more individuals are diagnosed with
neurodegenerative diseases and dementia, these costs will rise in coming years 10. Given these
personal and societal impacts, caregivers' concerns and wellbeing are a critical public health
interest 11.
The last decade has seen increased interest in caregiving concerns in neurodegenerative
disorders 12. Some cross-sectional studies showed that caregivers of individuals with ALS

13,14

and with frontotemporal dementia (FTD) report higher overall concerns and 15 especially when
compared with other neurodegenerative disorders, such as Alzheimer’s disease (AD) 16. Recent
cross-disorder work in (AD) and Parkinson’s disease (PD) showed that various types of
caregiving concerns exist across—not limited to specific—diagnoses 17. Possible contributors to
caregiving concerns include participant or care partner characteristics (e.g., age, sex) and
relationship role (e.g., spousal) 18, severity of communication impairment or needs driven
behaviors 19, increases of and difficulty with management of neuropsychiatric symptoms 20, and
decreased independence with basic and instrumental activities of daily living 21,22.
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The Zarit burden interview (ZBI) 23,24 is frequently used to assess caregiving burdens in
dementia and neurodegenerative disorders. Most work with the ZBI has focused on whether the
ZBI captures an overall burden (unidimensional), or if it captures multiple types of burdens
(multidimensional). An early study of ZBI dimensionality in the Canadian Study of Health and
Aging 25 showed two burden factors: “personal” and “role strains”. More recently, Oh and Kim 26
identified “social restrictions”, “self-criticism”, and “anger and frustration” in a Korean sample
of family caregivers for individuals with ALS. Smith et al.,

27

identified “impact of caregiving”,

“frustration/embarrassment”, and “uncertainty over the future” in a UK (Scotland) sample of
spousal or adult children caregivers across various diagnoses. While these showcase the variety
of burdens, sometimes, the same named type of burdens exist across the literature. For example,
Ankri et al., 28 and Springate & Tremont 29 each found three factors where one of those factors
was “guilt”. But these “guilt” types do not overlap.
The extant literature suggests that burdens are disorder specific. The literature also
suggests a wide variety of ZBI dimensionality and burden types. But given that the majority of
studies are not in representative and cross-disorder samples—and do not include comprehensive
and harmonized measures and approaches—what we see may only reflect particular aspects of
those studies. Therefore, it is unclear whether burdens are disorder specific, what types of
burdens exist, and importantly what characteristics are related to burden(s) (e.g., relationship
role, participant/partner characteristics, participant’s cognition). To help resolve some of the
conflicting results in the literature, we need a large and diverse sample of disorders,
comprehensive and harmonized measures, and suitable analyses to uncover dimensionality of the
ZBI.
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The Ontario Neurodegenerative Disease Research Initiative (ONDRI) 30,31 is a multisite,
prospective, observational, and longitudinal study neurodegenerative and cerebrovascular disease
cohorts: Alzheimer’s disease/mild cognitive impairment (AD/MCI), Parkinson’s disease (PD),
amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and cerebrovascular
disease (CVD). A central goal of ONDRI is to collect cohort-harmonized data across clinical,
neuropsychology, neuroimaging, genetics, gait and balance, oculomotor, and retinal imaging
platforms to better understand the comprehensive phenotypes of each disorder, the disease
impacts, and the contributions of cerebrovascular disease to dementia onset and progression.
Participants were recruited from fourteen academic health sciences centers across Ontario,
Canada (largely centered around six cities) and lived in a variety of communities including
urban, suburban, and rural settings. Given the longitudinal study design, and the extensive data
collection protocol, clinical participants were generally in early disease stages at baseline. All
assessments were completed at baseline and annually thereafter for the duration of the study. In
this study, we examined the following questions with the ONDRI data.
1. How many and what types of burdens are captured by the ZBI? This helps tell us what
the ZBI captures and how it can be used (in research and practice).
2. Do we see categorical or spectrum-like effects for burden(s)? This helps tell us if there
are effects specific to groups (e.g., FTD, spousal partners) or if there are common effects
across groups.
3. With ONDRI’s comprehensive and harmonized set of measures, which if any
demographic, clinical, and cognitive measures are related to burden(s)? This helps tell us,
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for examples, how memory, attention, symptoms, and disability of clinical participants
are related to study partners’ perceptions of burden(s).
Method
Diagnoses were based on the most recent criteria available at the time of recruitment, and
participants were recruited by experienced neurologists. For complete details and references on
diagnostic criteria see previous publications for recruitment targets31 and for characteristics of the
baseline sample30 (used here). Also see Supplemental Material. AD/MCI participants met the
NIA-AA criteria for probable AD, or single or multi-domain MCI 32,33. PD participants were
diagnosed via the UK Parkinson’s Disease Society Brain Bank criteria34. ALS participants met
the El Escorial criteria35. CVD participants are those that presented with ischemic stroke
documented by MRI or CT more than 3 months before recruitment36. FTD criteria were based on
various subtypes37–40.
Our study included N = 504 clinical participant-study partner dyads (those with available
ZBI data at baseline) from: AD/MCI (n = 120), ALS (n = 38), FTD (n = 53), PD (n = 136), and
CVD (n = 157). AD/MCI included MCI (n = 81), probable AD with amnestic presentation (n =
34), and probable AD with non-amnestic presentation (n = 5). FTD included behavioral variant
(n = 21), progressive supranuclear palsy (n = 15), nonfluent variant primary progressive aphasia
(n = 8), and n = 9 remaining individuals across semantic dementia, corticobasal syndrome, or
mixed FTD diagnoses. Of the N = 504 in this study, 497 had neuroimaging data at baseline with
stroke volume tracing 41. Overt stroke volumes were present in 85 CVD individuals, and a
combined 11 individuals across PD, FTD, and ALS. ONDRI participants were required to have
study partners. Study partners were individuals that had frequent interactions with the clinical
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participant (have contact at least once a month), had known the individual for more than 2 years,
and had to know the participant well enough to answer questions about the participant’s
cognitive abilities, communication skills, mood, and daily functioning. Study partners provided
information about the participant’s symptoms (physical, psychological, functional, behavioral,
and social abilities). Our sample included 334 male and 170 female clinical participants, with
129 male and 375 female study partners. The majority of clinical participants live in their own or
family homes (n = 498) with a small number of individuals in retirement homes or nursing
homes (combined n = 6). We grouped study partners into four relationship roles: domestic
partners (e.g., spouses, ex spouses, long term relationships; n = 387), adult children (including
grandchildren and in-laws; n = 66), siblings or parents (n = 18), and friends (n = 33). Of the
study partners, 408 lived with the clinical participant where 3 individuals had spent less than a
year living together, and 405 study partners and clinical participants lived together for a median
of 37 years (minimum = 1 year, maximum = 65 years). Of the 96 individuals who did not live
with the clinical participant, their estimated weekly time spent together was a median of 7.5
hours (minimum = 0.5 hours, maximum = 112 hours). See Table 1 for more details on
demographics and clinical measures.

Table 1
(A) Distribution of study partner types across the cohorts.
N = 504

DOMESTIC
PARTNERS
(N = 387)

CHILDREN
(N = 66)

SIBLINGS OR PARENTS
(N = 18)

FRIEND
(N = 33)

ADMCI (N = 120)

84

25

5

6

ALS (N = 38)

28

4

3

3
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FTD (N = 53)

41

8

2

2

PD (N = 136)

116

11

4

5

CVD (N = 157)

118

18

4

17

(B) Demographics of participants and study partners, with MoCA scores of participants
AGE
(med, min-max)
Overall (N = 504)
ADMCI (N = 120)
ALS (N = 38)
FTD (N = 53)
PD (N = 136)
CVD (N = 157)

68.78
[40.12 - 87.80]
70.93
[53.44 - 87.80]
63.71
[40.12 - 77.25]
69.13
[49.66 - 80.90]
68.10
[55.08 - 85.93]
68.85
[54.95 - 85.43]

SEX
(M/F)

SP AGE
(med, min-max)

334/170
66/54
22/16
34/19
106/30
106/51

64
[19 - 87]
67
[19 - 85]
60
[26 - 77]
62
[22 - 84]
64
[22 - 85]
65
[22 - 87]

SP SEX
(M/F)

LIVE
TOGETHER
(Y/N)

129/375

408/96

39/81

92/28

14/24

31/7

12/41

41/12

25/111

120/16

39/118

124/33

(C) Diagnostic history and severity
Modified Rankin
Scale
(med, min-max)
1
[0 - 4]
Missing = 67
1
[0 - 3]
Missing = 37

MoCA
(med, min-max)

Zarit’s Total Score
(med, min-max)

25
[13 - 30]
Missing = 1

14
[0 - 77]
Missing = 2

23
[15 - 30]

15.5
[0 - 55]

2
[0 - 4]

25
[19 - 30]
Missing = 1

19
[4 - 45]

2
[0 - 4]
Missing = 30

22
[13 - 29]

31
[4 - 77]

PD (N = 136)

2
[0 - 4]

26
[18 - 30]

CVD (N = 157)

1
[0 - 4]

26
[18 - 30]

Overall (N = 504)

ADMCI (N = 120)
ALS (N = 38)
FTD (N = 53)

11
[0 - 58]
Missing = 1
9
[0 - 64]
Missing = 1
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Note. ADMCI = Alzheimer’s Disease/Mild Cognitive Impairment, ALS = Amyotrophic Lateral Sclerosis, FTD =
Frontotemporal Dementia, PD = Parkinson’s Disease, CVD = Cerebrovascular Disease, MoCA = Montreal
Cognitive Assessment, SP = Study Partner, med = median, min = minimum, max = maximum. Missingness is
generally denoted per cell. (A) Shows the distribution of study partner types across cohorts. (B) Shows the ages and
sexes of the participants and their study partners within cohorts, and the proportion of clinical participant-study
partner dyads that live together. Ages are shown with median values and the minimum/maximum range of scores per
cohort. Precisions differ for ages because participant age was collected with month, day, and year, where study
partner age included only year. (C) modified Rankin scale, the MoCA scores for each cohort, and the Zarit’s Burden
Interview total score. Scores are shown with median values and the minimum/maximum range of scores per cohort.
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Measures
Most data were collected within 8 weeks of consent, except fourteen participants/study
partners exceeded 8 weeks, where three of those study partners completed the ZBI at 18, 26, and
35 weeks. Because of rare responses, a wide variety of possible response levels, and/or free text
based responses, we recoded levels of clinical participants’ education, study partner’s education,
household income, and study partner type. See the Appendix and Supplemental Materials for
more details on recoding and mappings between levels. Not all participants had data for all
measures. We note missingness as needed.
Study partners completed the ZBI, the Lawton scale for the participant’s basic and
instrumental activities of daily living (ADLs) 42, the Neuropsychiatric Inventory - Questionnaire
(NPI-Q) 43, and demographics. Participants completed the MoCA 44 (version 7) and a cognitive
battery 45 that had 26 measures from 14 neuropsychological tests across five domains
(attention/working memory, executive function, language, memory, and visuospatial abilities).
The brief visuospatial memory tests (BVMT; immediate and delayed recall and recognition
discrimination) were not part of the protocol for the ALS cohort. We used standardized scores
based on normative data or summary scores from the assessments. Some measures included
cutoffs. For example, the normative scores for BVMT immediate recall contained values from 20
to 80, with “<20” or >80” to indicate values below or above that cutoff; these values were treated
as ordinal. Missing data because of cognitive/behavioral issues were imputed to the worst
performance for the normative scores.
The ZBI is a 22 question self-report instrument to assess caregiving burdens. Each
question has five possible responses: “Never”, “Rarely”, “Sometimes”, “Quite Frequently”, and
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“Nearly Always”; traditionally recoded as 0, 1, 2, 3, and 4, respectively. Those numbers are
summed to compute a total score. However, individual question responses are not numeric and
should not be analyzed as such 46,47. ZBI responses are a mixture of categorical and ordinal: a
categorical response of “no” (Never) vs. “yes” (any other response), with ordinal “yes” responses
(“Rarely” < “Sometimes” < “Quite Frequently” < “Nearly Always”).
Statistical analyses
Data recoding. We recoded the ZBI as a hybrid of “crisp” and “fuzzy” coding 48–50 that
captures both the categorical “no” and the ordinal “yes”. For analyses, each question was
represented by three columns: a “no” column and two “yes” columns: a “low yes” and a “high
yes”. The “no” column is exclusively 0 or 1 when a response of “Never” occurred, and that
pattern was {1 0 0}. The “yes” responses could take on values of {0 1 0} for the “lowest yes”
and {0 0 1} for the “highest yes”. These are all “crisp” coding. A response of “Sometimes” could
take on values of {0 .667 .333}, which is an example of “fuzzy” coding. Some responses were
rare (e.g., less than ~5%) and thus combined with other responses. See the Appendix and
Supplemental Materials for more details and illustrations on this recoding.
Correspondence analysis. We used correspondence analysis (CA) 51, an approach akin
to principal components analysis, but designed specifically to handle the complexities of the ZBI
responses (i.e., hybrid categorical-ordinal). CA was designed for categorical and contingency
data but accommodates mixtures of data types. CA produces orthogonal components that are
new variables which are linear combinations of the original data. Components are ordered by
explained variance. CA produces scores for both the rows (participants) and columns (responses
to the ZBI).
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Resampling. We used split-half resampling (SHR) 52 to identify components to interpret.
SHR repeatedly splits the data into two independent and equally sized sets and performs CA.
Component reproducibility was estimated from the correlations between components derived
from each split. We used bootstrap resampling 53 to compute bootstrap ratios 54,55 that indicate
stability of responses (to each retained component). Bootstrap ratios are computed as the mean of
the bootstrap distributions divided by their standard deviation (akin to a Z-score). Resampling
preserved the proportions of the five cohorts. See the Appendix for more details on resampling.
Relationships between components and other measures. We analyzed the relationships
between components and the demographic, clinical, and cognitive measures. For categorical
variables (e.g., cohort, sex), we visualized distributions for levels along the component scores
with beeswarm plots with the 25, 50, and 75 percentiles. For numeric data, we computed
Spearman correlations between those data and the retained components. We computed
permutation based p-values 56 and bootstrap based 95% confidence (percentile) intervals 53. We
calculated the Hellinger distance between the full (100%) permutation (null) and bootstrap
(effect) distributions. Hellinger distance takes on a value of zero when the distributions are
identical, and a value of one when there is no overlap.
Results
Total ZBI scores were available for N = 502 (two study partners each left one response
blank). Table 1c and Figure 1a show the distribution of ZBI totals for each group. Our sample
median ZBI was 14 (see Table 1 for each group median). For the AD/MCI and FTD subtypes,
median scores were: 12 for MCI, 23 for amnestic AD, 31 for non-amnestic AD, 40 for
behavioral variant FTD, 22 for progressive supranuclear palsy, 17.5 for nonfluent variant
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primary progressive aphasia, and 31 for the remaining FTD subtypes. Figure 1a shows the
distributions, medians, and quartiles for each cohort, and Figure 1b shows the proportion of
responses. Short names for the ZBI and which questions they map to are in Supplemental
Materials. Figure 1b helps highlight the nonlinearity in responses.
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Figure 1: A (top) and B (bottom). A (top) shows the total summary scores for the N = 502 complete cases broken
down by cohort, with boxplots that reflect the 25%, 50%, and 75%-iles. B (bottom) shows distributions of responses
to each question for N = 504, with missing values displayed as “No Response”. ADMCI = Alzheimer’s
Disease/Mild Cognitive Impairment, ALS = Amyotrophic Lateral Sclerosis, FTD = Frontotemporal Dementia, PD =
Parkinson’s Disease, CVD = Cerebrovascular Disease. In (B) we see the proportion of responses to each question
(rank ordered by proportion of “Never” responses). Any unlabeled proportion is < 9%. The proportions help
highlight the frequent and rare responses, and also highlight a non-linearity of responses. Each item is preceded by
its question number on the Zarit’s burden interview. See also Supplemental Figure 2 for recruitment cohort versions
of this plot.
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Missing responses for the ZBI were imputed to the mean after the hybrid crisp/fuzzy
coding. Some responses were rare (e.g., less than ~5%) and combined with other responses (see
Appendix). We flipped the signs of the components so that each component had a positive
correlation with the ZBI total. Resampling was performed 1,000 times. Split-half resampling
showed that the first three components had reproducibility |r| = 0.999, |r| = 0.980, and |r| =
0.655, with explained variance of 24.89%, 8.76%, and 4.01%, respectively (see Appendix for
more information).
Figure 2 shows the distributions of study partner component scores colored by the
participants’ respective cohorts (Fig. 2a), and the responses component scores colored by the
three levels used for the crisp/fuzzy coding (Fig. 2b). We used a bootstrap ratio cut-off of a
magnitude of 4—approximately p = 0.00003 (one tailed)—for emphasis in Fig. 2b (responses
with magnitudes less than 4 are denoted in grey). Component 1 shows nearly all responses are
stable and that Component 1 is a gradient from “No” to “Low Yes” to “High Yes”. Component 2
shows a gradient of individuals from (1) a general and low overall burdens, to (2) an absence of
specific burdens, to (3) presence of specific high burdens. Component 3 shows a pattern with (1)
“High Yes” responses for embarrassment and strain with “No” responses on doing a better job
and should do more vs. (2) “High Yes” response to insufficient money, both “Low Yes” and
“High Yes” to wanting to do a better job, and “No” responses to embarrassment and anger.
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Figure 2: A (top) and B (bottom) the participant and variable component scores respectively. In both the solid
horizontal line denotes zero on the Component. (A) Participant scores for the first three components, with each dot
colored to represent the participant’s recruitment cohort. Shown as a “beeswarm” plot, which distributes the
individual dots with respect to their density (distribution). (B) Variable component scores for the first three
components, with each dot colored to represent the coded response level if was stable under bootstrap resampling;
else the dot is unlabeled and colored as grey. The dots are presented along a line (i.e., the component), with labels
that are “repelled” from the dot to ensure readability. Each label is the short form of the question (see Supplemental
Material for short codes and bootstrap ratios).
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ZBI structure and demographic, clinical, and cognitive characteristics
Figure 3 shows the original component scores (see Fig. 2a), visualized separately for
cohort (Fig. 3a), study partner relationship type (Fig. 3b). Notable effects include: (1) the FTD
group had higher Component 1 scores (Fig. 2a), (2) the ALS group had slightly higher
Component 3 scores (Fig. 2a), (3) friends and “siblings/parents” had lower Component 1 scores
(Fig. 3b), and (4) “siblings/parents” had slightly higher Component 3 scores (Fig. 3b). In
Appendix, we provide additional visualizations including participant sex, study partner sex, if
they live together, participant education, study partner education, household income, and
presence/absence of stroke in the participant. Generally, these show no effects.
Table 2 shows correlations between components and numeric variables. The ZBI total
score was strongly correlated with the first component—r(N = 502) = 0.987—but weakly
correlated with Components 2 and 3: r(N = 502) = 0.207 and r(N = 502) = 0.156, respectively.
We emphasize interpretation of correlations where the Hellinger distances between the
permutation and bootstrap distributions were at or near 1.
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Figure 3: A (top) and B (bottom) shows the same component scores as in Figure 3a, but now broken down
by cohort and study partner relationship role. The component scores across the three components shown per (A)
cohort and (B) study partner relationship role. For panel (A) ADMCI = Alzheimer’s Disease/Mild Cognitive
Impairment, ALS = Amyotrophic Lateral Sclerosis, FTD = Frontotemporal Dementia, PD = Parkinson’s Disease,
CVD = Cerebrovascular Disease. All distributions are presented as “beeswarm” plots—which distribute the dots
outward based on density—and notched boxplots that show the median (middle) and the 25% (bottom) and 75%
(top) percentiles.
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As Component 1 scores increased (1) ADL scores decreased (lower scores indicate
higher levels of dependence): instrumental ADL r(N = 475) = -.566, pperm < 0.001 with bootstrap
CI = [-0.614, -0.511], basic ADL % r(N = 484) = -.430, pperm < 0.001 with bootstrap CI =
[-0.489, -0.366], and (2) NPI-Q scores increased (higher scores indicate increased severity or
distress): severity r(N = 468) = .585, pperm < 0.001 with bootstrap CI = [0.53, 0.633], distress r(N
= 460) = .587, pperm < 0.001 with bootstrap CI = [0.531, 0.636].
We saw many cognitive measures that had stable correlations with Component 1. We
focus here on those with high Hellinger distances (~.95), which indicate that the permutation
(null) and bootstrap (effect) distributions had little-to-no overlap. As Component 1 scores
increased, MoCA scores and most of the cognitive measures decreased, including: (i) three of
our seven attention & working memory measures, (ii) all six of our executive function tasks, (iii)
one of our four language tasks, and (iv) five of our six memory tasks. None of our visuospatial
tasks were strongly related to Component 1. See Table 2 for all of correlation values, bootstrap
CIs, permutation p-values, and Hellinger distances between the permutation (null) and bootstrap
(effect) distributions between our measures and the ZBI components. See Appendix for a
visualization of the correlations in Table 2.
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Table 2
Correlations of components with other measures.
Component 1

Component 2

Component 3

ZBI total (N = 502)

r = 0.987, p < 0.001
CI = [0.984, 0.989]
HD = 1

r = 0.207, p < 0.001
CI = [0.118, 0.301]
HD = 0.953

r = 0.156, p = 0.001
CI = [0.088, 0.227]
HD = 0.907

MoCA total (N = 503)

r = -0.268, p < 0.001
CI = [-0.336, -0.201]
HD = 0.995

r = -0.065, p = 0.073
CI = [-0.142, 0.008]
HD = 0.484

r = 0.013, p = 0.387
CI = [-0.062, 0.093]
HD = 0.152

Participant Age (N = 504)

r = -0.046, p = 0.153
CI = [-0.123, 0.029]
HD = 0.373

r = 0.025, p = 0.292
CI = [-0.058, 0.1]
HD = 0.209

r = -0.114, p = 0.008
CI = [-0.187, -0.045]
HD = 0.767

Study Partner Age (N = 504)

r = -0.103, p = 0.016
CI = [-0.176, -0.03]
HD = 0.714

r = 0.003, p = 0.479
CI = [-0.07, 0.076]
HD = 0.092

r = -0.145, p = 0.001
CI = [-0.216, -0.072]
HD = 0.863

Instrumental ADLs % (N = 475)

r = -0.566, p < 0.001
CI = [-0.617, -0.515]
HD = 1

r = -0.065, p = 0.078
CI = [-0.151, 0.013]
HD = 0.487

r = -0.047, p = 0.144
CI = [-0.124, 0.029]
HD = 0.396

Basic ADLs % (N = 484)

r = -0.43, p < 0.001
CI = [-0.493, -0.369]
HD = 1

r = 0.033, p = 0.245
CI = [-0.048, 0.11]
HD = 0.263

r = -0.128, p = 0.004
CI = [-0.201, -0.055]
HD = 0.801

NPI-Q Severity Total (N = 468)

r = 0.586, p < 0.001
CI = [0.534, 0.636]
HD = 1

r = 0.038, p = 0.204
CI = [-0.039, 0.126]
HD = 0.31

r = 0.057, p = 0.11
CI = [-0.013, 0.134]
HD = 0.455

NPI-Q Distress Total (N = 460)

r = 0.587, p < 0.001
CI = [0.536, 0.638]
HD = 1

r = 0.036, p = 0.222
CI = [-0.043, 0.124]
HD = 0.287

r = 0.04, p = 0.208
CI = [-0.034, 0.116]
HD = 0.313

Summary and demographics

Activities of daily living

Neuropsychiatric inventory Questionnaire
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Cognitive battery

Attention & Working Memory

Symbol Digit Modality Test
(N = 504)

r = -0.294, p < 0.001
CI = [-0.365, -0.228]
HD = 0.999

r = -0.064, p = 0.076
CI = [-0.135, 0.012]
HD = 0.476

r = -0.003, p = 0.474
CI = [-0.074, 0.075]
HD = 0.086

Trail Making Test – Part A
(N = 499)

r = -0.199, p < 0.001
CI = [-0.271, -0.133]
HD = 0.982

r = -0.036, p = 0.21
CI = [-0.109, 0.037]
HD = 0.311

r = 0.002, p = 0.482
CI = [-0.079, 0.081]
HD = 0.104

WAIS-III: Digit Span Forward
(N = 503)

r = -0.119, p = 0.002
CI = [-0.192, -0.046]
HD = 0.773

r = -0.091, p = 0.015
CI = [-0.163, -0.016]
HD = 0.648

r = -0.034, p = 0.23
CI = [-0.107, 0.034]
HD = 0.309

WAIS-III: Digit Span Backward
(N = 502)

r = -0.115, p = 0.005
CI = [-0.196, -0.039]
HD = 0.748

r = -0.028, p = 0.271
CI = [-0.105, 0.044]
HD = 0.245

r = -0.075, p = 0.051
CI = [-0.145, -0.006]
HD = 0.578

WAIS-III: Digit Span Total
(N = 500)

r = -0.13, p = 0.001
CI = [-0.205, -0.057]
HD = 0.818

r = -0.06, p = 0.079
CI = [-0.132, 0.012]
HD = 0.466

r = -0.049, p = 0.123
CI = [-0.119, 0.018]
HD = 0.419

DKEFS: Color naming
(N = 499)

r = -0.244, p < 0.001
CI = [-0.316, -0.178]
HD = 0.989

r = -0.03, p = 0.279
CI = [-0.1, 0.043]
HD = 0.253

r = -0.007, p = 0.44
CI = [-0.084, 0.069]
HD = 0.119

DKEFS: Word reading
(N = 501)

r = -0.166, p < 0.001
CI = [-0.24, -0.097]
HD = 0.915

r = -0.041, p = 0.194
CI = [-0.112, 0.028]
HD = 0.316

r = -0.004, p = 0.453
CI = [-0.079, 0.072]
HD = 0.081

Trail Making Test – Part B
(N = 485)

r = -0.252, p < 0.001
CI = [-0.322, -0.183]
HD = 0.994

r = -0.059, p = 0.102
CI = [-0.135, 0.017]
HD = 0.446

r = -0.023, p = 0.299
CI = [-0.1, 0.058]
HD = 0.217

DKEFS: Interference
(N = 499)

r = -0.207, p < 0.001
CI = [-0.277, -0.138]
HD = 0.977

r = -0.024, p = 0.308
CI = [-0.096, 0.048]
HD = 0.215

r = -0.031, p = 0.24
CI = [-0.108, 0.042]
HD = 0.258

Executive Function
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DKEFS: Switching
(N = 494)

r = -0.238, p < 0.001
CI = [-0.305, -0.175]
HD = 0.995

r = -0.051, p = 0.128
CI = [-0.125, 0.02]
HD = 0.402

r = 0.01, p = 0.403
CI = [-0.067, 0.087]
HD = 0.109

DKEFS: Letter Fluency
(N = 504)

r = -0.22, p < 0.001
CI = [-0.288, -0.153]
HD = 0.989

r = -0.062, p = 0.097
CI = [-0.136, 0.012]
HD = 0.469

r = -0.033, p = 0.233
CI = [-0.107, 0.043]
HD = 0.266

DKEFS: Category Fluency
(N = 501)

r = -0.253, p < 0.001
CI = [-0.323, -0.18]
HD = 0.994

r = -0.082, p = 0.032
CI = [-0.159, -0.01]
HD = 0.596

r = 0.03, p = 0.256
CI = [-0.051, 0.106]
HD = 0.26

WASI-II: Matrix Reasoning
(N = 495)

r = -0.213, p < 0.001
CI = [-0.282, -0.145]
HD = 0.983

r = -0.07, p = 0.057
CI = [-0.145, 0]
HD = 0.546

r = -0.008, p = 0.43
CI = [-0.081, 0.064]
HD = 0.127

Boston Naming – 15 Item
(N = 429)

r = -0.145, p < 0.001
CI = [-0.22, -0.069]
HD = 0.853

r = -0.075, p = 0.065
CI = [-0.158, 0.006]
HD = 0.525

r = -0.077, p = 0.041
CI = [-0.151, 0.006]
HD = 0.558

TAWF: Verb Naming
(N = 504)

r = -0.205, p < 0.001
CI = [-0.277, -0.131]
HD = 0.965

r = -0.069, p = 0.057
CI = [-0.147, 0.008]
HD = 0.524

r = -0.044, p = 0.141
CI = [-0.119, 0.03]
HD = 0.365

BDAE: Semantic Probe (raw)
(N = 497)

r = -0.078, p = 0.032
CI = [-0.156, -0.007]
HD = 0.606

r = -0.065, p = 0.074
CI = [-0.142, 0.007]
HD = 0.487

r = -0.094, p = 0.02
CI = [-0.169, -0.019]
HD = 0.645

WASI-II: Vocabulary
(N = 489)

r = -0.153, p < 0.001
CI = [-0.233, -0.082]
HD = 0.885

r = -0.054, p = 0.1
CI = [-0.131, 0.021]
HD = 0.439

r = -0.011, p = 0.383
CI = [-0.089, 0.064]
HD = 0.146

RAVLT: Immediate
(N = 502)

r = -0.265, p < 0.001
CI = [-0.336, -0.198]
HD = 0.997

r = -0.085, p = 0.024
CI = [-0.165, -0.015]
HD = 0.641

r = 0.054, p = 0.11
CI = [-0.018, 0.126]
HD = 0.412

RAVLT: Long-delay
(N = 501)

r = -0.18, p < 0.001
CI = [-0.254, -0.111]
HD = 0.947

r = -0.06, p = 0.086
CI = [-0.141, 0.013]
HD = 0.481

r = 0.08, p = 0.052
CI = [0.006, 0.154]
HD = 0.573

Language

Memory
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RAVLT: Recognition
Discrimination
(N = 498)

r = -0.09, p = 0.019
CI = [-0.16, -0.022]
HD = 0.671

r = 0.003, p = 0.475
CI = [-0.072, 0.078]
HD = 0.074

r = -0.006, p = 0.429
CI = [-0.078, 0.068]
HD = 0.101

BVMT-R: Immediate*
(N = 466)

r = -0.258, p < 0.001
CI = [-0.328, -0.187]
HD = 0.996

r = -0.102, p = 0.012
CI = [-0.177, -0.028]
HD = 0.693

r = 0.004, p = 0.469
CI = [-0.08, 0.082]
HD = 0.107

BVMT-R: Delayed*
(N = 466)

r = -0.253, p < 0.001
CI = [-0.323, -0.18]
HD = 0.988

r = -0.059, p = 0.09
CI = [-0.135, 0.02]
HD = 0.446

r = -0.018, p = 0.334
CI = [-0.102, 0.062]
HD = 0.19

BVMT-R: Recognition
Discrimination*
(N = 465)

r = -0.234, p < 0.001
CI = [-0.307, -0.159]
HD = 0.994

r = -0.019, p = 0.329
CI = [-0.103, 0.056]
HD = 0.207

r = 0.018, p = 0.368
CI = [-0.063, 0.095]
HD = 0.151

Judgment of Line Orientation
(N = 501)

r = -0.048, p = 0.137
CI = [-0.127, 0.025]
HD = 0.374

r = -0.01, p = 0.419
CI = [-0.077, 0.063]
HD = 0.128

r = 0.004, p = 0.461
CI = [-0.067, 0.074]
HD = 0.134

VOSP: Incomplete Letters
(N = 503)

r = -0.115, p = 0.003
CI = [-0.186, -0.046]
HD = 0.767

r = -0.028, p = 0.264
CI = [-0.107, 0.051]
HD = 0.222

r = 0.058, p = 0.092
CI = [-0.022, 0.13]
HD = 0.459

BVMT-R: Copy Trial
(N = 502)

r = 0.001, p = 0.486
CI = [-0.077, 0.073]
HD = 0.095

r = 0.016, p = 0.367
CI = [-0.061, 0.088]
HD = 0.157

r = -0.005, p = 0.425
CI = [-0.082, 0.068]
HD = 0.098

Visuospatial

Note. ZBI = Zarit’s Burden Interview, MoCA = Montreal Cognitive Assessment, ADLs = activities of daily living,
NPI-Q = neuropsychiatric inventory questionnaire, CI = Confidence interval, HD = Hellinger distance. Spearman
correlations between additional (numeric) measures and the components. The additional measures are grouped
together as (i) demographics and summary, which includes the Zarit and MoCA totals, as well as ages, (ii)
percentage scores of the instrumental and basic activities of daily living (ADL), (iii) the neuropsychiatric inventory
questionnaire, and (iv) individual measures from neuropsychology protocol of 14 tests, grouped by their theoretical
domain; the ‘*’ denotes the BVMT was not part of the ALS cohort’s protocol. Signs of the correlations must only be
interpreted with respect to the components and strictly within components (i.e., signs across components are
arbitrary). We provide permutation-based p-values, bootstrap-based 95% confidence intervals, and the Hellinger
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distance between the permutation and bootstrap distributions. See Supplemental Materials on the number of
individuals imputed for each task.

Figure 4 visualizes Components 2 and 3 together, where Figure 4a shows study partner
component scores and Figures 4b-c show ZBI responses. Figure 4a shows that few individuals
exist strictly along Component 2 or Component 3, rather, individuals and responses exist in the
quadrants. The upper right reflects “current care”, characterized by strain of caregiving, desire to
do more, and should do a better job of caregiving. The upper left reflects “future care”,
characterized by responses about the ability to care for much longer, insufficient money for care,
and uncertainty of what to do. The lower left reflects both the presence of “personal” and the
absence of “clinical participant-based” responses, with higher (“high yes”) responses to
embarrassment and strain, with “never” responses to afraid of the future, the need to do more and
dependence. The lower right reflects “social” responses, with generally lower (“low yes”)
responses to questions on comfort around family and friends, care by others, and embarrassment.
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Figure 4: Visualization of Components 2 and 3 with (A) at the top and (C) at the bottom; (A) shows the participant
component scores and (B-C) show the variable component scores. (A) Shows the participant component scores
colored by their Component 1 score (which reflects a general overall burden from low to high). (B) Shows the
variable component scores, colored by response type. Items colored only if bootstrap ratios > |4| on Component 2.
(C) Shows the variable component scores, colored by response type. Items colored only if bootstrap ratios > |4| on
Component 3.
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Discussion

Four conclusions emerged from our study. First, we found strong relationships between
Component 1 (“overall burden”) and neuropsychiatric symptoms and activities of daily living.
Second, study partners expressed concerns at the individual level (not necessarily diagnosis or
relationship). Third, study partners expressed four types of care-related concerns (Components 2
and 3) subsequent to an overall burden (Component 1). Finally, two ZBI questions stood out that
could be useful as screening questions.
The ONDRI ZBI score was lower than comparable studies (e.g., Hébert et al., 2000
median ZBI = 18.5; ONDRI’s median ZBI = 14), and we also observed weaker relationships
between clinical participants’ cognition and “overall burden” than other studies

57–59

. ONDRI’s

ALS and FTD groups showed elevated “overall burden” compared to the other groups, where
ONDRI’s FTD effect was driven almost entirely by the behavioral variant subtype. The strongest
relationships we saw were between “overall burden” and (higher) severity of and distress over
neuropsychiatric symptoms, and (lower) activities of daily living, a finding supported by other
studies 14,15,60–62. While most studies are only within disorders 58,61,63–65, we provided a
disease-agnostic approach which highlights that concerns are expressed at the individual level,
not necessarily at a group level.
The literature is inconsistent regarding relationship roles. Spousal partners and adult
children differ on overall burden in Alzheimer’s

66

but not FTD 67. Pinquart and Sorenson’s

meta-analysis 68 showed that spousal partners and adult children instead differ on types of (not
overall) burdens. We showed neither: “spousal partner” and “adult children” did not differ on any
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of our components. We also saw no differences for other demographic factors (e.g., education or
income): a result that both agrees with 25 and contradicts 69 previous studies.
We identified four types of concerns subsequent to overall burden: current care of the
person with the neurodegenerative disorder, future care of the person with the neurodegenerative
disorder, personal concerns of the study partner, and social concerns of the study partner. Though
we identified these four types (see Figure 4), it is worth noting that some of the individual
questions may have low endorsement. For example, Figure 1 shows that a substantial majority
(81%) of respondents said “Never” to “Do you wish you could leave the care of your relative to
someone else?”; a question we consider a “social concern” (lower right of Figs. 4b and 4c).
When our four types are considered with the overall proportions (see Figure 1), it is clear that
some types have higher endorsement. In particular, we generally see that questions about current
and future care have higher endorsements than other questions.
None of the concerns we identified strictly reflect objective vs. subjective concerns 20, but
some reflect stress and demand 19. Many recent efforts within 26–29 and beyond 70–72
neurodegenerative disorders also identify multiple types of concerns.
From our analyses, two questions stood out: “Are you afraid of what the future holds for
your relative?” and “Do you feel your relative is dependent on you?” (see Figure 1b). A high
response to the future question reflects concerns about future care, a high response to the
dependence question reflects personal/dependence stressors, and a high response to both reflects
high overall concern. These two questions might be useful as a screening assessment that could
guide clinicians in two ways: (1) the need for additional help and resources on understanding
neurodegenerative disorders, or an indicator of disease progress (“are you afraid of what the
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future”), and (2) help assess the well-being of the caregiver (“is your relative dependent on you”)
who may require, for example, additional or external assistance with caregiving duties. However,
following these two questions, clinicians should follow up with more detailed quantitative and
qualitative assessments to get a more complete picture of the needs for both the individual living
with a neurodegenerative disorder and the caregiver.
Limitations
Some study partners were possibly not caregivers, though the majority were spousal (N =
387/504) and/or lived with the clinical participants (N = 408/504). The number of hours spent
caregiving was an overlooked measure at the time of protocol development. Our study and
similar studies would benefit from clearly identifying the relationships between, and how much
care a study partner provides. ONDRI did not collect valuable measures on the study partners,
such as quality of life, cognitive, psychological well-being (e.g., depression, anxiety) 25, and
personality measures (e.g., neuroticism, optimism, pessimism) 73. Together, these measures and
more formal measures of caregiving (e.g., specific duties, time spent, financial contributions)
could help clarify the relationships between various types of burdens and well-being of the
clinical participant-study partner dyads.
Our participants were recruited across numerous regions in Ontario (urban, suburban, and
rural areas). Some similar effects to ours can be seen in other, more focused and smaller
international studies 14,15,17,60–62. Our sample is considerably larger than most and, importantly,
includes a more diverse sample with respect to disorders. The majority of our study partners
were females providing care for males, but that reflects the population of dementia caregivers 74.
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For ONDRI, our participants had varying levels of impairment within and across
disorders, but approximately half of each cohort (and thus whole sample) were above/below the
MoCA impairment cut-off. Also, our analyses were on baseline data (i.e., recruitment into
ONDRI), so many clinical participants were in early stages of disease. Because these are baseline
data, severity and types of burdens could change at subsequent visits, and as disorders progress.
The longitudinal component of ONDRI will be a vital resource to understand stability or change
of types of caregiving burdens, especially with respect to the course(s) of disease(s).
Conclusions
We showed that caregiving concerns are multidimensional and highly individualized
regardless of differing symptom profiles across neurodegenerative disorders. Our results
reinforce the importance of developing caregiver support interventions and education programs
that reduce the burden of completing activities of daily living and managing neuropsychiatric
symptoms. Our results also highlight key caregiver concerns with planning for future care and
meeting their social needs.
We can make several recommendations to address both clinical and research needs. First,
research and clinical practice require better (1) general purpose and disease-specific measures of
concerns and (2) definitions of concerns and burdens within, across, and beyond disorders. More
accurate measurement will be critical in coming years, especially because an increasing number
of individuals prefer to age at home and more likely with familial caregivers. Though it is clear
that types of concerns exist across many studies—which includes our own—it is not clear what
those types are or how we should define and measure them. Though we provide names for the
concerns we identified in our data, others may interpret them differently.
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Short assessments are beneficial to screen for and identify those in most need of support
for caregiving 75. Treatment strategies should consider both the individual living with a
neurodegenerative disorder and caregivers/relatives as a unit: those with neurodegenerative
disorders are assessed and treated for disorders, and caregivers/relatives are assessed on their
well-being and ability to provide care. Healthcare professionals can help serve the dyadic unit by
directing caregivers to more resources. One approach is to suggest resources for strategies like
Goal Attainment Scaling 76, self-care 77–79, and social support 80. Additionally, psychoeducation
on disorder trajectories and characteristics, and resources on how neurodegeneration leads to
physical and cognitive, as well as personality, judgement, and social functioning changes. This
would be especially important—and beneficial—in low prevalence disorders.
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